血清LDL-P与LDL-C检测结果一致性分析

doi:10.3969/j.issn.1673-8640.2023.02.009

检验医学 ›› 2023, Vol. 38 ›› Issue (2): 148-152.DOI: 10.3969/j.issn.1673-8640.2023.02.009

血清LDL-P与LDL-C检测结果一致性分析

苏珍珍¹, 邹继华², 王惠民³, 徐炜烽², 丁方⁴, 张晶梅⁵(), 王占科²()

1.河北北方学院医学检验学院，河北张家口 075000
2.美康盛德医学检验所血脂研究院，浙江宁波 315040
3.南通大学附属医院检验科，江苏南通 226019
4.宁波鄞州中医院神经康复科，浙江宁波 315040
5.邢台市第三院输血科，河北邢台 054000

收稿日期:2022-01-08 修回日期:2022-05-19 出版日期:2023-02-28 发布日期:2023-04-17
通讯作者: 王占科，E-mail：wangzhanke@sina.com；张晶梅，E-mail：504565370@qq.com。
作者简介:苏珍珍，女，1995年生，技师，主要从事临床检验工作。
基金资助:
邢台市科技局重点课题(2020ZC358)

Consistency of serum LDL-P and LDL-C determination results

SU Zhenzhen¹, ZOU Jihua², WANG Huimin³, XU Weifeng², DING Fang⁴, ZHANG Jingmei⁵(), WANG Zhanke²()

1. Academy of Medical Laboratory，Hebei North University，Zhangjiakou 075000，Hebei，China
2. Ningbo Meikang Shengde Medical Laboratory Lipid Research Institute，Ningbo 315040，Zhejiang，China
3. Department of Clinical Laboratory，the Affiliated Hospital of Nantong University，Nantong 226019，Jiangsu，China
4. Department of Neurorehabilitation，Ningbo Yinzhou Hospital of Traditional Chinese Medicine，Ningbo 315040，Zhejiang，China
5. Department of Blood Transfusion，the Third Hospital of Xingtai，Xingtai 054000，Hebei，China

Received:2022-01-08 Revised:2022-05-19 Online:2023-02-28 Published:2023-04-17

摘要/Abstract

摘要：

目的探讨基于垂直密度梯度离心（VAP）法检测低密度脂蛋白颗粒（LDL-P）与生化均相法检测低密度脂蛋白胆固醇（LDL-C）的一致性。方法选取冠状动脉粥样硬化性心脏病患者417例和健康体检者154名，采用VAP法检测LDL-P，采用生化均相法检测LDL-C。分别以3.37 mmol/L和1 000 nmol /L作为LDL-C和LDL-P参考区间的上限。将LDL-C和LDL-P结果一致的样本纳入A组，再细分为A1组（LDL-C和LDL-P结果均正常）和A2组（LDL-C和LDL-P结果均升高）；将LDL-C和LDL-P结果不一致的样本纳入B组，再细分为B1（LDL-C正常、LDL-P升高）和B2组（LDL-C升高、LDL-P正常）。采用Pearson相关分析评估各项指标之间的相关性。结果 Pearson相关分析结果显示，LDL-C与LDL-P呈正相关（r=0.666，P=0.000）。A组合计为181例（31.70%），其中A1组95例（16.64%）、A2组86例（15.06%）；B组合计为390例（68.30%），其中B1组373例（65.32%）、B2组17例（2.98%）。结论 LDL-C与LDL-P不一致的情况主要为LDL-P升高，临床应关注LDL-P检测结果，避免对LDL-C水平正常人群的漏检。

关键词: 低密度脂蛋白颗粒, 低密度脂蛋白胆固醇, 垂直密度梯度离心, 一致性

Abstract:

Objective To investigate the consistency between the determination of low-density lipoprotein particles（LDL-P） by vertical auto profile（VAP） and the determination of low-density lipoprotein cholesterol（LDL-C） by biochemical homogeneity. Methods A total of 417 patients with coronary atherosclerotic heart disease and 154 healthy subjects were enrolled to determine LDL-P by VAP and LDL-C level by biochemical homogeneity. The 3.37 mmol/L and 1 000 nmol/L were used as the upper limits of the reference intervals for LDL-C and LDL-P，respectively. The samples with consistent LDL-C and LDL-P results were included in group A and classified into group A1（both LDL-C and LDL-P results were normal） and group A2（both LDL-C and LDL-P results were elevated） according to the determination results. The samples with inconsistent LDL-C and LDL-P results were classified into group B，and they were classified into B1（LDL-C normal，LDL-P elevated） and B2（LDL-C elevated，LDL-P normal）. Pearson correlation analysis was used to assess the correlation between the indicators. Results The results of Pearson correlation analysis showed that LDL-C and LDL-P were positively correlated（r=0.666，P=0.000）. There were 181 cases（31.70%） in group A，including 95 cases（16.64%） in group A1 and 86 cases（15.06%） in group A2. There were 390 cases（68.30%） in group B，including 373 cases（65.32%） in group B1 and 17 cases（2.98%） in group B2. Conclusions The inconsistency between LDL-C and LDL-P is mainly present in patients with high LDL-P，suggesting that LDL-P should be clinically concerned to prevent missed determination in subjects with normal LDL-C levels.

Key words: Low-density lipoprotein particle, Low-density lipoprotein cholesterol, Vertical auto profile, Consistency

中图分类号:

R446.1

苏珍珍, 邹继华, 王惠民, 徐炜烽, 丁方, 张晶梅, 王占科. 血清LDL-P与LDL-C检测结果一致性分析[J]. 检验医学, 2023, 38(2): 148-152.

SU Zhenzhen, ZOU Jihua, WANG Huimin, XU Weifeng, DING Fang, ZHANG Jingmei, WANG Zhanke. Consistency of serum LDL-P and LDL-C determination results[J]. Laboratory Medicine, 2023, 38(2): 148-152.

图/表 1

参考文献 22

[1]	MICHOS E D, MCEVOY J W, BLUMENTHAL R S. Lipid management for the prevention of atherosclerotic cardiovascular disease[J]. N Engl J Med, 2019, 381(16):1557-1567. DOI URL
[2]	JELLINGER P S, HANDELSMAN Y, ROSENBLIT P D, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease-executive summary[J]. Endocr Pract, 2017, 23(4):479-497. DOI URL
[3]	WOLSKA A, REMALEY A T. Measuring LDL-cholesterol:what is the best way to do it?[J]. Curr Opin Cardiol, 2020, 35(4):405-411. DOI URL
[4]	GERMAN C A, SHAPIRO M D. Assessing atherosclerotic cardiovascular disease risk with advanced lipid testing:state of the science[J]. Eur Cardiol, 2020, 15:e56. DOI URL
[5]	BORÉN J, CHAPMAN M J, KRAUSS R M, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease:pathophysiological,genetic,and therapeutic insights:a consensus statement from the European Atherosclerosis Society Consensus Panel[J]. Eur Heart J, 2020, 41(24):2313-2330. DOI URL
[6]	DELATOUR V, CLOUET-FORAISON N, GAIE-LEVREL F, et al. Comparability of lipoprotein particle number concentrations across ES-DMA,NMR,LC-MS/MS,immunonephelometry,and VAP:in search of a candidate reference measurement procedure for apoB and non-HDL-P standardization[J]. Clin Chem, 2018, 64(10):1485-1495. DOI URL
[7]	梁纯子, 朱满, 伍仕敏, 等. VAP+技术在高三酰甘油血症患者血浆LDL-C和LDL-P检测中的应用[J]. 临床检验杂志, 2020, 38(2):90-94.
[8]	孙晓, 吕礼应. 血清脂蛋白(a)颗粒浓度与质量浓度检测方法的比较及其临床应用[J]. 临床检验杂志, 2021, 39(2):90-93.
[9]	印中鹏, 吴嘉, 汪俊军. 慢性肾脏疾病患者血清脂蛋白(a)颗粒浓度与质量浓度检测结果的差异比较[J]. 中华检验医学杂志, 2021, 44(7):6.
[10]	尚红, 王毓三, 申子瑜. 全国临床检验操作规程[M]. 4 版. 北京: 人民卫生出版社, 2015.
[11]	TOTH P P, GRABNER M, PUNEKAR R S, et al. Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets[J]. Atherosclerosis, 2014, 235(2):585-591. DOI PMID
[12]	GRUNDY S M, STONE N J, BAILEY A L, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. Circulation, 2019, 139(25):e1082-e1143.
[13]	MACH F, BAIGENT C, CATAPANO AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias:lipid modification to reduce cardiovascular risk[J]. Eur Heart J, 2020, 41(1):111-188. DOI URL
[14]	ADAY A W, LAWLER P R, COOK N R, et al. Lipoprotein particle profiles,standard lipids,and peripheral artery disease incidence[J]. Circulation, 2018, 138(21):2330-2341. DOI URL
[15]	WILLIAMS P T, ZHAO X Q, MARCOVINA S M, et al. Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease[J]. Atherosclerosis, 2014, 233(2):713-720. DOI PMID
[16]	梁纯子, 朱满, 涂建成. VAP检测血浆脂蛋白亚组分的新进展及应用分析[J]. 检验医学, 2019, 34(1):76-81.
[17]	KULKARNI K R. Cholesterol profile measurement by vertical auto profile method[J]. Clin Lab Med, 2006, 26(4):787-802. DOI PMID
[18]	邹继华, 张维, 沈敏, 等. 血清脂蛋白亚组分和脂蛋白(a)分离技术的研究进展[J]. 检验医学, 2021, 36(10):1078-1086.
[19]	CROMWELL W C, OTVOS J D, KEYES M J, et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study-implications for LDL management[J]. J Clin Lipidol, 2007, 1(6):583-592. DOI URL
[20]	MILLER W G, MYERS G L, SAKURABAYASHI I, et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures[J]. Clin Chem, 2010, 56(6):977-986. DOI PMID
[21]	冯仁丰. 致动脉粥样硬化的是LDL-C还是LDL颗粒?[J]. 检验医学, 2013, 28(11):957-964.
[22]	BHANPURI N H, HALLBERG S J, WILLIAMS P T, et al. Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year:an open label,non-randomized,controlled study[J]. Cardiovasc Diabetol, 2018, 17(1):56. DOI

血清LDL-P与LDL-C检测结果一致性分析

Consistency of serum LDL-P and LDL-C determination results

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 22

相关文章 15

编辑推荐

Metrics

[1]	伏艺, 杨雪松, 金立钢, 翟红礼, 金小玲. sd-LDL-C与ACS患者远期不良心血管事件发生的相关性[J]. 检验医学, 2023, 38(9): 878-883.
[2]	马建国, 李洪春. 冠心病患者血脂水平与心功能指标的相关性[J]. 检验医学, 2023, 38(7): 659-664.
[3]	邢宝宝, 曹银芳. sd-LDL-C/LDL-C比值对AMI患者介入治疗后支架内再狭窄的预测价值[J]. 检验医学, 2023, 38(10): 941-945.
[4]	张一帆, 李长平, 张莉莉, 陈忠. 不同年龄心血管疾病患者血浆半乳凝集素3与低密度脂蛋白胆固醇的相关性[J]. 检验医学, 2023, 38(1): 8-13.
[5]	杨雪, 徐翀, 宋颖, 赵强, 缪颖波, 王青, 周靖. 长三角三地全血细胞计数检测结果一致性研究[J]. 检验医学, 2022, 37(4): 387-391.
[6]	鞠颖慧, 莫惠芳, 吴蕙, 陈朴, 郭玮, 王蓓丽. 2种6色流式细胞术试剂检测淋巴细胞亚群的性能比较[J]. 检验医学, 2022, 37(3): 270-273.
[7]	沈盈, 徐晓萍, 张乐乐, 杜勇平, 孟超. 非空腹血液样本LDL-C检测的临床应用价值[J]. 检验医学, 2022, 37(11): 1049-1056.
[8]	岳道远, 陈薇, 廖庆, 余微婷, 李辉军. 武汉地区糖化血红蛋白一致性计划的建立和评价[J]. 检验医学, 2022, 37(1): 78-82.
[9]	吕献敏, 虞国其, 陈铮铮, 姜黎花, 颜鲁伟, 费鲜明. 基于钾、钠、总钙项目探讨异常检验结果复查前后的一致性[J]. 检验医学, 2021, 36(8): 843-846.
[10]	陆银华, 朱宇清, 赵晓君, 曹丹如, 朱岭峰, 顾志冬. 不同检测系统抗HCV抗体灰区样本检测一致性分析[J]. 检验医学, 2021, 36(7): 700-704.
[11]	彭琰君, 韩雪晶, 唐红霞, 陈俊萌, 贾克刚. 核磁共振波谱法与传统生化检测方法血脂检测结果相关性分析[J]. 检验医学, 2021, 36(7): 733-737.
[12]	李静, 全晖, 曾志荣, 韦祎. 成都地区表观健康者小而密低密度脂蛋白胆固醇参考区间建立[J]. 检验医学, 2021, 36(6): 609-614.
[13]	王微, 王蕾, 王蓓丽, 周芳芳, 胡军, 吴佩, 殷奋, 袁开影, 侯玉敏, 刁端勤, 李国颖, 陈敏, 高雨红. 上海市徐汇区HbA_1c检测一致性计划的建立和初步评价[J]. 检验医学, 2021, 36(5): 549-553.
[14]	欧元祝, 陈宝荣, 居漪. 临床化学检测的标准化现状[J]. 检验医学, 2021, 36(3): 240-244.
[15]	赵晶晶, 张鹏, 周湧, 曹颖平, 黄之虎, 符生苗, 王玉明, 洪国粦, 沈军, 郑磊. 中国南部地区表观健康人群Lp-PLA2水平分布及其与LDL-C、hs-CRP的相关性分析[J]. 检验医学, 2021, 36(12): 1222-1228.